Apathy as a herald of cognitive changes in multiple sclerosis: A 2-year follow-up study

2019 ◽  
Vol 26 (3) ◽  
pp. 363-371 ◽  
Author(s):  
Simona Raimo ◽  
Daniele Spitaleri ◽  
Luigi Trojano ◽  
Gabriella Santangelo

Background: Behavioral symptoms, such as apathy and depression, are common in multiple sclerosis (MS) but their relationship with cognitive and clinical characteristics often remains underinvestigated and not monitored over time. Objective: The aim of this study was to assess the evolution of cognitive profile of patients affected by MS in relation to apathy and depression using a 2-year follow-up study. Methods: Two years after the first assessment, 100 of 125 MS patients were re-evaluated on a comprehensive neuropsychological battery, and on specific scales for assessment of apathy (Apathy Evaluation Scale—Self-reported) and depression (Hamilton Depression Rating Scale). Results: After 2 years (T1), we found a relatively consistent prevalence of apathy (about 40%) and a reduction in prevalence of depression (from 44% to 30%). Higher level of apathy at baseline predicted the progressive cognitive changes at follow-up; and patients with apathy without depression (“pure” apathy) than patients without apathy had poorer performance on the interference task of the Stroop test assessing inhibitory control. Conclusion: The present results suggested that apathy in MS was associated with more severe executive dysfunctions (in particular cognitive control). Apathy rather than depression predicted cognitive impairment in MS over time.

Author(s):  
Soundarya Soundararajan ◽  
Arpana Agrawal ◽  
Meera Purushottam ◽  
Shravanthi Daphne Anand ◽  
Bhagyalakshmi Shankarappa ◽  
...  

2021 ◽  
pp. 089033442110301
Author(s):  
Hannah G. Juncker ◽  
M. Romijn ◽  
Veerle N. Loth ◽  
Tom G. Caniels ◽  
Christianne J.M. de Groot ◽  
...  

Background: Human milk contains antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) following Coronavirus Disease 2019 (COVID-19). These antibodies may serve as protection against COVID-19 in infants. However, the evolution of these human milk antibodies over time is unclear. Research Aim: To elucidate the evolution of immunoglobulin A (IgA) against SARS-CoV-2 in human milk after a SARS-CoV-2 infection. Methods: This longitudinal follow-up study included lactating mothers ( N = 24) who had participated in the COVID MILK study. To assess the evolution of SARS-CoV-2 antibodies, serum and human milk samples were collected 14–143 days after the onset of clinical symptoms related to COVID-19. Enzyme-Linked ImmunoSorbent Assay was used to detect antibodies against the ectodomain of the SARS-CoV-2 spike protein. Results: SARS-CoV-2 antibodies remain present up to 5 months (143 days) in human milk after onset of COVID-19 symptoms. Overall, SARS-CoV-2 IgA in human milk seems to gradually decrease over time. Conclusion: Human milk from SARS-CoV-2 convalescent lactating mothers contains specific IgA antibodies against SARS-CoV-2 spike protein up to at least 5 months post-infection. Passive viral immunity can be transferred via human milk and may serve as protection for infants against COVID-19. Dutch Trial Register on May 1st, 2020, number: NL 8575, URL: https://www.trialregister.nl/trial/8575 .


2010 ◽  
Vol 33 (2) ◽  
pp. 169-175 ◽  
Author(s):  
Jorge Sepulcre ◽  
Herminia Peraita ◽  
Joaquín Goñi ◽  
Gonzalo Arrondo ◽  
Iñigo Martincorena ◽  
...  

2004 ◽  
Vol 56 (2) ◽  
pp. 303-306 ◽  
Author(s):  
Sean J. Pittock ◽  
Robyn L. McClelland ◽  
William T. Mayr ◽  
Neal W. Jorgensen ◽  
Brian G. Weinshenker ◽  
...  

2017 ◽  
Vol 372 ◽  
pp. 201
Author(s):  
Darija Kisic-Tepavcevic ◽  
Tatjana Pekmezovic ◽  
Goran Trajkovic ◽  
Nebojsa Stojsavljevic ◽  
Irena Dujmovic ◽  
...  

2003 ◽  
Vol 9 (6) ◽  
pp. 616-620 ◽  
Author(s):  
Scott B Patten ◽  
Shanika Fridhandler ◽  
Cynthia A Beck ◽  
Luanne M Metz

Background: Recent side effect data from clinical trials of interferon beta in multiple sclerosis (MS) have failed to confirm that these medications are associated with an increased risk of depression. However, these studies have used highly selected samples and the results may not be generalizable to real world settings. Methods: C linical data on subjects from southern A lberta who have applied for, or are receiving, public reimbursement for MS treatment are maintained in a database at the University of C algary Multiple Sclerosis C linic. Depression ratings obtained using the C enter for Epidemiological Studies Depression Rating Scale (C ES-D) are included in this database. In the current analysis, these longitudinal data were used to determine whether depressive symptoms were associated with disease-modifying treatments. Results: A t baseline, ratings were available for 163 subjects. Those choosing interferon beta resembled those choosing glatiramer acetate in most respects. During follow-up, no differences were observed in the prevalence or incidence of depression and C ES-D scores were not found to differ between the treatment groups. Conclusions: The failure to identify higher rates of depression both in previous intervention studies and in the current observational study provides confirmation that these drugs are not substantially associated with the occurrence of depression.


2011 ◽  
Vol 33 ◽  
pp. S12-S13 ◽  
Author(s):  
E. Venturini ◽  
L. Balugani ◽  
F. Zarattin ◽  
G. Ferraresi ◽  
S. Straudi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document